Jounce Therapeutics to Present at Upcoming Investor Conferences in September
September 02 2021 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
company management will participate at several upcoming investor
conferences in September:
- 2021 Wells Fargo Virtual
Healthcare Conference: Fireside chat on Friday September
10, 2021 at 8:00 a.m. ET.
- H.C. Wainwright 23rd Annual
Global Investment Conference: Presentation will be
available on-demand during the conference, starting on Monday,
September 13, 2021 at 7:00 a.m. ET.
- Baird’s 2021 Global
Healthcare Conference: Presentation on Wednesday,
September 15, 2021 at 12:15 p.m. ET.
- 2021 Cantor Fitzgerald Virtual Global Healthcare
Conference: Presentation on Wednesday, September 29, 2021
at 4:00 p.m. ET.
A webcast of the presentations will be available by visiting
“Events and Presentations” in the Investors and Media section of
Jounce’s website at www.jouncetx.com. A replay of the webcasts will
be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has multiple development stage programs ongoing while
simultaneously advancing additional early-stage assets from its
robust discovery engine based on its Translational Science
Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2
(ILT4) receptor antagonist shown to reprogram immune-suppressive
tumor associated macrophages to an anti-tumor state in preclinical
studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a
monotherapy and in combination with pimivalimab (formerly
JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling
patients with advanced solid tumors. Jounce’s most advanced product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS and is currently being studied in the SELECT Phase 2
trial. Pimivalimab is a PD-1 inhibitor intended for combination use
in the INNATE and SELECT trials and with Jounce’s broader pipeline.
Additionally, Jounce obtained IND clearance for and exclusively
licensed worldwide rights to JTX-1811, a monoclonal antibody
targeting CCR8 and designed to selectively deplete T regulatory
cells in the tumor microenvironment, to Gilead Sciences, Inc. For
more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Mark YoreJounce Therapeutics, Inc.+1-857-200-1255
myore@jouncetx.com
Julie SeidelStern Investor
Relations+1-212-362-1200Julie.Seidel@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024